Cencora reports Q2 adjusted EPS $4.42, consensus $4.10

Reports Q2 revenue $75.5B, consensus $75.8B. “Cencora’s (COR) second quarter results reflect the strength of our value proposition as a healthcare services provider and the important role we play in the supply chain, driven by our pharmaceutical distribution footprint and complementary end-to-end services and solutions,” said Robert P. Mauch, President and Chief Executive Officer of Cencora. “We continue to advance our core business and enhance our capabilities, with a focus on elevating our solutions in the markets we serve.” “Cencora strives to enhance its leadership position in healthcare through our pharmaceutical centric strategy, best-in-class team members, and customer-focused approach.” Mauch continued. “We believe this leadership, coupled with our operational excellence and emphasis on productivity, drives our resilient financial performance now and will continue to drive it in the future.”